Navigation Links
GEN reports on recent progress in Alzheimer's research
Date:8/7/2012

New Rochelle, NY, August 7, 2012The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN). The current therapeutic market is valued at $3 to $4 billion, shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease, according to a recent issue of GEN.

"Despite all the research on amyloid plaques and neurofibrillary tangles there is still a debate on whether these biological phenomena are causative or symptomatic of Alzheimer's," said John Sterling, Editor-in-Chief of GEN. "Once scientists can clearly and unequivocally define key factors related to the actual biology of the disease itself, therapeutic advances could take place much more quickly."

More than 150 companies are working in the Alzheimer's space, including approximately 15 multinationals and 30 generics companies. A number of these firms are taking innovative approaches to tackling this extremely debilitating disease. For example, the USPTO in March granted a patent for Antisenilin, developed by Intellect Neurosciences. This therapy, which targets either end of -amyloid, is in Phase III trials.

Baxter has a Phase III program under way for Gammagard, a naturally occurring plasma-derived immunoglobulin for moderate-stage AD patients. The trial runs until February 2013. Phase II results suggest Gammagard may positively affect brain atrophy and cognition. The compound already is approved for immunodeficiency diseases.

Other companies covered in the GEN article include AstraZeneca, Roche, TransTech Pharma, Astex Pharmaceuticals, Memory Pharmaceuticals, Sanofi-Aventis, Eli Lilly, GE Healthcare Life Sciences, and Charles River Laboratories.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
2. Aware, Inc. Reports Second Quarter 2012 Financial Results
3. GEN reports on growth of tissue engineering revenues
4. BGI reports the completed sequence of foxtail millet genome
5. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
6. Aware, Inc. Reports First Quarter 2012 Financial Results
7. From 503-million-year-old fungi to recent earthquakes: New Geology posted ahead of print
8. House funding bill will delay research progress and place new burdens on NIH
9. Guam conservation efforts progress
10. New report evaluates progress of Everglades Restoration Plan
11. Progress in Osteoporosis re-launched with new design, now invites commentary
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GEN reports on recent progress in Alzheimer's research
(Date:7/9/2019)... Del. (PRWEB) , ... July 08, 2019 , ... ... Court ruled in favor of Danisco’s ownership of the innovation behind two Danisco ... that an entitlement action could be based on prior art was without merit ...
(Date:6/25/2019)... ... , ... ActX has launched a medical genetic interpretation ... can get access to professionally reviewed genetic screening similar to what a physician ... + Ancestry customers., With the ActX + 23andMe service, both 23andMe customers and ...
(Date:6/19/2019)... LAS VEGAS (PRWEB) , ... June 19, 2019 , ... ... on improving physicochemical properties of Cefazolin Sodium, antibiotic which can prove to be beneficial ... Over 519% increase in residue amount , Over 68% decrease in ...
Breaking Biology News(10 mins):
(Date:6/26/2019)... ... June 26, 2019 , ... Alice Branton today released research results from preclinical ... Magnesium Gluconate, which can prove to be beneficial for treating Hypomagnesemia. , The preclinical ... change in crystallite size , Over 142% increase in particle size , ...
(Date:6/11/2019)... ... June 10, 2019 , ... Thought Technology Ltd is pleased ... Biofeedback Tech Ltd as its authorised distributor for the UK and ... therapeutic treatments and clinical assessment protocols to treat stress related disorders as well ...
(Date:6/11/2019)... ... June 11, 2019 , ... Veterinary Regenerative ... Inc. (PSC) , has announced that their GMP facility for cell production is ... for manufacturing. This is an important milestone for VetStem as it expands ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... USPTO providing proprietary interest to our methodology, processes, and diagnostic techniques. The ... TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring methodology. The ...
Breaking Biology Technology: